Renee Lentini - ImmunoGen VP Officer

IMGNDelisted Stock  USD 18.20  0.81  4.26%   

Insider

Renee Lentini is VP Officer of ImmunoGen
Age 46
Phone781 895 0600
Webhttps://www.immunogen.com

ImmunoGen Management Efficiency

The company has return on total asset (ROA) of (0.0849) % which means that it has lost $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1988) %, meaning that it created substantial loss on money invested by shareholders. ImmunoGen's management efficiency ratios could be used to measure how well ImmunoGen manages its routine affairs as well as how well it operates its assets and liabilities.
ImmunoGen currently holds 15.24 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. ImmunoGen has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ImmunoGen's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Prof MDHookipa Pharma
81
Klaus OrlingerHookipa Pharma
47
Remy SukhijaMadrigal Pharmaceuticals
52
Sharen PyatetskayaHepion Pharmaceuticals
N/A
David MBASeres Therapeutics
63
Stephen MDHepion Pharmaceuticals
N/A
Alexandra HughesWilsonMereo BioPharma Group
54
Renato SkerljX4 Pharmaceuticals
N/A
Rebecca MDMadrigal Pharmaceuticals
73
Brian SullivanElevation Oncology
N/A
Kevin PharmDAxsome Therapeutics
46
MBBS MDMereo BioPharma Group
54
Marine PopoffHookipa Pharma
N/A
David DornanElevation Oncology
47
Michael EsqTG Therapeutics
59
Arthur TaverasX4 Pharmaceuticals
61
William JDAkero Therapeutics
52
Janetta TrochimiukPDS Biotechnology Corp
62
Weidong ZhongTerns Pharmaceuticals
58
Murray MDX4 Pharmaceuticals
63
Kerry MDTerns Pharmaceuticals
N/A
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people. ImmunoGen (IMGN) is traded on NASDAQ Exchange in USA and employs 277 people.

Management Performance

ImmunoGen Leadership Team

Elected by the shareholders, the ImmunoGen's board of directors comprises two types of representatives: ImmunoGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoGen. The board's role is to monitor ImmunoGen's management team and ensure that shareholders' interests are well served. ImmunoGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel JD, VP Officer
Susan Altschuller, VP CFO
MMSc MD, VP Officer
Lauren MBA, Senior Officer
Renee Lentini, VP Officer
Stacy Coen, Sr Officer
Audrey Bergan, Senior Officer
Courtney OKonek, Senior Relations
Isabel Kalofonos, Senior Officer
Anabel Chan, Head Relations
FACP MD, VP Affairs
Mark Enyedy, President CEO, Director
Theresa Wingrove, Vice President - Regulatory Affairs and Quality
Stacy MBA, Senior Officer

ImmunoGen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmunoGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with ImmunoGen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.

Moving against ImmunoGen Stock

  0.89JNJ Johnson JohnsonPairCorr
  0.82KO Coca Cola Earnings Call This WeekPairCorr
  0.8PTAIY Astra International TbkPairCorr
  0.77PTITF PT Indosat Tbk Earnings Call This WeekPairCorr
  0.74TLK Telkom Indonesia TbkPairCorr
The ability to find closely correlated positions to ImmunoGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunoGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunoGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunoGen to buy it.
The correlation of ImmunoGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunoGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunoGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunoGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Consideration for investing in ImmunoGen Stock

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Transaction History
View history of all your transactions and understand their impact on performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon